ethinyl estradiol/drosperinone (Ocella, Yasmin, Gianvi, Vestura)
Jump to navigation
Jump to search
Indications
- Combination monophasic oral contraceptive.
Contraindications
Cautions:
- patients at risk of hyperkalemia
- NOT a weight-loss agent[2]
Dosage
ethinyl estradiol: 30 ug
drospirenone: (progestin with antimineralocorticoid activity)
Adverse effects
- drospirenone may increase serum K+ levels[4]
- drospirenone may increase of venous thromboembolism[5]
Drug interactions
- concurrent administration agents increasing serum K+
- drug interaction(s) of beta-adrenergic receptor antagonists with oral contraceptives
- drug interaction(s) of NSAIDs with oral contraceptive
Notes
Manufacturer: Berlex (Yasmin)
More general terms
Components
References
- ↑ Prescriber's Letter 8(6):34 2001
- ↑ 2.0 2.1 Prescriber's Letter 9(2):S1 2002
- ↑ Prescriber's Letter 9(11):63 2002
- ↑ 4.0 4.1 Prescriber's Letter 16(10): 2009 Safety of Drospirenone-Containing Oral Contraceptives Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251007&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 FDA Safety Alert: Posted 05/31/2011 Birth Control Pills Containing Drospirenone: Possible Increased Risk of Blood Clots http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm257337.htm
- ↑ Wikipedia: Ethinylestradiol/drospirenone https://en.wikipedia.org/wiki/Ethinylestradiol/drospirenone